{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:43:35Z","timestamp":1791297815102,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Randomized trials of procalcitonin-guided algorithms to discontinue antibiotics in critically ill patients with sepsis report reduced antibiotic duration and possible mortality benefit. However, open-label trial designs, inconsistent algorithm adherence, and unclear stewardship practices have limited confidence in procalcitonin's benefit. The ADAPT-Sepsis trial addressed several of these gaps through a concealed intervention, robust stewardship, and head-to-head comparison with C-reactive protein (CRP). Procalcitonin-guided care reduced antibiotic use without significantly impacting mortality, although CRP-guided care showed no benefit. However, algorithm adherence was suboptimal, and the absolute reduction in antibiotic duration with procalcitonin was only 1 day. As shorter fixed-duration therapy becomes standard, procalcitonin's utility in the intensive care unit may decline. Embedding procalcitonin and other biomarkers into multifaceted stewardship strategies, and addressing barriers to clinician trust and implementation, is essential. Future research should also evaluate whether biomarker use earlier in the sepsis care pathway, particularly in Emergency Departments, can improve diagnostic accuracy and enhance patient outcomes.<\/jats:p>","DOI":"10.1093\/cid\/ciaf336","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T08:01:01Z","timestamp":1750320061000},"page":"453-458","source":"Crossref","is-referenced-by-count":12,"title":["Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-1236","authenticated-orcid":false,"given":"Simran","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-4498","authenticated-orcid":false,"given":"Michael","family":"Klompas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Population Medicine, Harvard Medical School\/Harvard Pilgrim Health Care Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-4245","authenticated-orcid":false,"given":"Chanu","family":"Rhee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Population Medicine, Harvard Medical School\/Harvard Pilgrim Health Care Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2026031619514547400_ciaf336-B1","doi-asserted-by":"crossref","first-page":"e00635-18","DOI":"10.1128\/AAC.00635-18","article-title":"Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults","volume":"62","author":"Tansarli","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514547400_ciaf336-B2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkt177","article-title":"Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u20147 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"Eliakim-Raz","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514547400_ciaf336-B3","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031619514547400_ciaf336-B4","first-page":"1065","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","author":"BALANCE Investigators, for the Canadian Critical Care Trials Group","year":"2024","journal-title":"N Engl J Med"},{"key":"2026031619514547400_ciaf336-B5","doi-asserted-by":"crossref","first-page":"dlae215","DOI":"10.1093\/jacamr\/dlae215","article-title":"Antibiotic duration for common bacterial infections: a systematic review","volume":"7","author":"Mo","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026031619514547400_ciaf336-B6","doi-asserted-by":"crossref","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","article-title":"Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use","volume":"3","author":"Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026031619514547400_ciaf336-B7","doi-asserted-by":"crossref","first-page":"ofw249","DOI":"10.1093\/ofid\/ofw249","article-title":"Using procalcitonin to guide antibiotic therapy","volume":"4","author":"Rhee","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514547400_ciaf336-B8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1473-3099(12)70323-7","article-title":"Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis","volume":"13","author":"Wacker","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026031619514547400_ciaf336-B9","doi-asserted-by":"crossref","first-page":"ofac179","DOI":"10.1093\/ofid\/ofac179","article-title":"Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission","volume":"9","author":"Relph","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514547400_ciaf336-B10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/thoraxjnl-2020-214896","article-title":"Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia","volume":"75","author":"Gautam","year":"2020","journal-title":"Thorax"},{"key":"2026031619514547400_ciaf336-B11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"2026031619514547400_ciaf336-B12","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201408-1483OC","article-title":"Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial","volume":"190","author":"Shehabi","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031619514547400_ciaf336-B14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026031619514547400_ciaf336-B15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1164\/rccm.202004-1201OC","article-title":"Procalcitonin to reduce long-term infection-associated adverse events in sepsis: a randomized trial","volume":"203","author":"Kyriazopoulou","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031619514547400_ciaf336-B16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.chest.2018.12.029","article-title":"Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis","volume":"155","author":"Pepper","year":"2019","journal-title":"Chest"},{"key":"2026031619514547400_ciaf336-B17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13054-023-04677-2","article-title":"Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival\u2014a systematic review and meta-analysis","volume":"27","author":"Papp","year":"2023","journal-title":"Crit Care"},{"key":"2026031619514547400_ciaf336-B18","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1097\/CCM.0000000000006366","article-title":"Benefits and harms of procalcitonin- or C-reactive protein-guided antimicrobial discontinuation in critically ill adults with sepsis: a systematic review and network meta-analysis","volume":"52","author":"Kubo","year":"2024","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/CCM.0000000000002928","article-title":"Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis","volume":"46","author":"Iankova","year":"2018","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CCM.0000000000002953","article-title":"Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies","volume":"46","author":"Lam","year":"2018","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2024.26458","article-title":"Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-sepsis randomized clinical trial","volume":"333","author":"Dark","year":"2025","journal-title":"JAMA"},{"key":"2026031619514547400_ciaf336-B22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3949\/ccjm.86a.18074","article-title":"Can procalcitonin guide decisions about antibiotic management?","volume":"86","author":"Fakheri","year":"2019","journal-title":"Cleve Clin J Med"},{"key":"2026031619514547400_ciaf336-B23","first-page":"333","article-title":"Procalcitonin for diagnosis, risk assessment, and prognosis of respiratory tract infections","volume":"106","author":"Yancey","year":"2022","journal-title":"Am Fam Physician"},{"key":"2026031619514547400_ciaf336-B24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13054-018-2234-3","article-title":"Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in The Netherlands","volume":"22","author":"Kip","year":"2018","journal-title":"Critical Care"},{"key":"2026031619514547400_ciaf336-B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12879-020-05246-6","article-title":"Hospital physicians\u2019 experiences with procalcitonin\u2014implications for antimicrobial stewardship; a qualitative study","volume":"20","author":"Christensen","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026031619514547400_ciaf336-B26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcrc.2020.02.009","article-title":"A real-world assessment of procalcitonin combined with antimicrobial stewardship in a community ICU","volume":"57","author":"Langford","year":"2020","journal-title":"J Crit Care"},{"key":"2026031619514547400_ciaf336-B27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/jep.13299","article-title":"Procalcitonin utilization in the real world: an observational study of antibiotic prescribing practices","volume":"26","author":"Choi","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"2026031619514547400_ciaf336-B28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/CCM.0000000000005968","article-title":"Reliability of admission procalcitonin testing for capturing bacteremia across the sepsis spectrum: real-world utilization and performance characteristics, 65 U.S. hospitals, 2008\u20132017","volume":"51","author":"Lawandi","year":"2023","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B29","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/ajhp\/zxac341","article-title":"Procalcitonin for sepsis management: implementation within an antimicrobial stewardship program","volume":"80","author":"Fugit","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"2026031619514547400_ciaf336-B30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/1060028017753411","article-title":"A collaborative approach to improve consistent use of procalcitonin in lower respiratory tract infections","volume":"52","author":"Levine","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2026031619514547400_ciaf336-B31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2009.1297","article-title":"Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial","volume":"302","author":"Schuetz","year":"2009","journal-title":"JAMA"},{"key":"2026031619514547400_ciaf336-B32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-guided use of antibiotics for lower respiratory tract infection","volume":"379","author":"Huang","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031619514547400_ciaf336-B33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/CCM.0000000000006241","article-title":"Can procalcitonin and other biomarkers help rapidly identify sepsis among undifferentiated high-risk patients in the emergency department?","volume":"52","author":"Rhee","year":"2024","journal-title":"Crit Care Med"},{"key":"2026031619514547400_ciaf336-B34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/ciaf118","article-title":"Frequency of antibiotic overtreatment and associated harms in patients presenting with suspected sepsis to the emergency department: a retrospective cohort study","volume":"80","author":"Shappell","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf336\/63537530\/ciaf336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/453\/63537530\/ciaf336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/453\/63537530\/ciaf336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:52:21Z","timestamp":1773705141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/3\/453\/8170036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf336","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,6,20]]}}}